Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.
We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.
We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.
Learn more about our Cardio Analysis Services
Experts in cardiac safety
Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.
A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia
2
November 2023
Exciting findings from a Phase 1/2 first-in-human study on HMB-001 for Glanzmann thrombasthenia have been published in Blood (2023).
Promising Results for Zilebesiran in Phase 1 Study
29
September 2023
We are pleased to share the findings from our recent Phase 1 study, which investigated the potential of Zilebesiran, an investigational RNA interference therapeutic.
Exciting Research Update: Enhancing Blinding in Clinical Trials with Auto-Injectors
5
September 2023
We’re excited to share the findings of our recent study on the use of auto-injector systems (A-INJ) in randomized controlled trials (RCTs) by Dr Jorg Taubel, Dr Ulrike Lorch, Dr Thomas York and Vishal Aggarwal.
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
21
July 2023
Our research on behalf of Anylam Pharmaceuticals for a novel anti-hypertensive injectable, Zilbesiran, has been featured in the prestigious New England Journal of Medicine.
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.